US FDA approves deferiprone (Ferriprox) twice-daily tablets for treatment of iron overload due to thalassemia syndromes

Deferiprone tablets currently available in the UK (Ferriprox; 500mg, 1000mg) are licensed as to be taken three times a day. The new formulation of 1000mg oral tablets eliminates the midday dose. The application for marketing approval was supported by bioequivalence studies.


Biospace Inc.